Fig. 3. The proportion of patients with cancer demonstrating post-3rd dose antibody response.

Data extracted and for some studies split by patients with haematological cancer (H) and patients with solid cancer (S). Zeng et al. [35] used a neutralisation assay to assess antibody response against Delta and Omicron which is presented separately.